TriSalus Life Sciences (TLSI) Payables (2020 - 2026)

TriSalus Life Sciences' Payables history runs 7 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Payables rose 50.82% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 50.82% increase from a year earlier, with the FY2025 full-year figure at $3.0 million, up 32.01% from the prior year.
• Payables advanced to $4.2 million in Q1 2026 per TLSI's latest filing, from $3.0 million in the prior quarter.
• Across five years, Payables topped out at $12.7 million in Q2 2023 and bottomed at $1.4 million in Q3 2024.
• The 5-year median for Payables is $2.3 million (2024), against an average of $3.6 million.
• Across the five-year window, Payables soared 644.03% in 2023 and slumped 84.46% in 2024, its largest moves.
• Year by year, Payables stood at $7.4 million in 2022, then sank by 54.17% to $3.4 million in 2023, then plunged by 32.94% to $2.3 million in 2024, then jumped by 32.01% to $3.0 million in 2025, then surged by 40.97% to $4.2 million in 2026.
• Per Business Quant, the three latest TLSI Payables figures stand at $4.2 million (Q1 2026), $3.0 million (Q4 2025), and $3.8 million (Q3 2025).